<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163487</url>
  </required_header>
  <id_info>
    <org_study_id>ENT0031</org_study_id>
    <secondary_id>SU-05052010-5866</secondary_id>
    <secondary_id>18245</secondary_id>
    <nct_id>NCT01163487</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers</brief_title>
  <official_title>Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel T. Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on
      recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor
      hypoxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of DCA in patients with recurrent head and neck cancer who have failed first-line therapy.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Cancers</condition>
  <arm_group>
    <arm_group_label>Dichloroacetate (DCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dichloroacetate</intervention_name>
    <description>25-50mg/kg per day; oral</description>
    <arm_group_label>Dichloroacetate (DCA)</arm_group_label>
    <other_name>DCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EF5</intervention_name>
    <description>21 mg/kg; IV</description>
    <arm_group_label>Dichloroacetate (DCA)</arm_group_label>
    <other_name>EF-5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed head and neck squamous cell carcinoma

          -  Age &gt; 18 years old

          -  Patients must have unresectable disease in which there is no accepted potentially
             curative treatment option

          -  Patients must have acceptable organ and marrow function as defined below:

          -  leukocytes &gt;3,000/uL

          -  absolute neutrophil count &gt;1,500/uL

          -  platelets &gt;90,000/uL

          -  total bilirubin &lt;=1.5X normal institutional limits

          -  AST(SGOT)/ALT(SGPT) &lt;=2.5 X normal institutional limits with the following exceptions:

               1. Patients with documented tumors involving the liver who have Grade &lt;2 elevations
                  in AST, ALT, and/or alkaline phosphatase are eligible if &lt;5X ULN.

               2. Patients with documented tumors involving bone who have a Grade &lt;2 elevation in
                  alkaline phosphatase are eligible if &lt;5X ULN.

          -  creatinine &lt;=1.5X normal institutional limits OR creatinine clearance &gt;50 mL/min on
             the basis of the Cockcroft-Gault glomerular filtration rate estimation

          -  Patients must have non-cranial gross disease that is greater than 1 cm on CT scan
             prior to enrollment

          -  Disease must be FDG-avid on PET scanning

          -  Creatinine within normal institutional limits

          -  Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix 1)

          -  Life expectancy &gt; 12 weeks

          -  Both men and women and members of all races and ethnic groups are eligible for this
             trial.

        Exclusion Criteria:

          -  Women who are pregnant

          -  Administration of any systemic cytotoxic agents within the last 2 weeks of enrollment

          -  Patients who are unwilling or unable to provide informed consent

          -  Patients who have potentially curable disease

          -  Participation in another concurrent treatment protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel T Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Daniel T. Chang</investigator_full_name>
    <investigator_title>Assistant Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

